Clywedog reports final Phase Ib trial results for balomenib

​

Clywedog Therapeutics has reported final results from a Phase Ib trial of its investigational oral drug balomenib in adults with type 2 diabetes, with reductions in HbA1c and fasting plasma glucose maintained after treatment ended.

The post Clywedog reports final Phase Ib trial results for balomenib appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.